Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Monday, 02'nd Feb 2026
Organon (OGN) concluded the recent trading session at $8.2, signifying a -3.98% move from its prior day's close.
Organon Completes Divesture of JADA System to Laborie Medical
02:31pm, Thursday, 29'th Jan 2026
OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
07:30am, Thursday, 29'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.
Organon Completes Divestiture of JADA® System to Laborie
12:45pm, Wednesday, 28'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
Orogen Royalties' Exploration Stage Projects and Royalties Update and 2026 Outlook
07:30am, Monday, 26'th Jan 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 26, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded explo
Organon (OGN) Outperforms Broader Market: What You Need to Know
07:00pm, Wednesday, 21'st Jan 2026
Organon (OGN) concluded the recent trading session at $9.59, signifying a +1.37% move from its prior day's close.
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
12:11pm, Tuesday, 20'th Jan 2026
OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
10:31am, Tuesday, 20'th Jan 2026
India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
06:51pm, Thursday, 15'th Jan 2026
In the closing of the recent trading day, Organon (OGN) stood at $8.7, denoting a +1.05% move from the preceding trading day.
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
07:01pm, Wednesday, 14'th Jan 2026
Organon (OGN) reached $8.61 at the closing of the latest trading day, reflecting a +2.14% change compared to its last close.
Organon & Co. (NYSE:OGN) Receives $8.38 Consensus Price Target from Brokerages
02:16am, Wednesday, 14'th Jan 2026
Organon and Co. (NYSE: OGN - Get Free Report) has earned a consensus recommendation of "Reduce" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four res
Comparing Embecta (NASDAQ:EMBC) & Organon & Co. (NYSE:OGN)
02:14am, Tuesday, 13'th Jan 2026
Organon and Co. (NYSE: OGN - Get Free Report) and Embecta (NASDAQ: EMBC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
01:30am, Thursday, 08'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Organon & Co. Sees Unusually High Options Volume (NYSE:OGN)
01:29am, Wednesday, 07'th Jan 2026
Organon and Co. (NYSE: OGN - Get Free Report) saw unusually large options trading on Tuesday. Stock investors acquired 17,794 call options on the stock. This is an increase of 550% compared to the ave
